new version V2017

Liraglutide antidiabetic drugs
Description Results

victoza - liraglutide      

  • Group by...

pdf
TrialStudied treatmentControl treatmentpatientsROBResultNCT

diabetes type 2

NN2211-1796liraglutide other dosesplacebo (add on MET) - NCT00614120
Madsbad (vs Glimepiride), 2004liraglutide other dosesglimepiride Exploratory Suggesting
Madsbad (vs placebo), 2004liraglutide other dosesplaceboNegative
Harder, 2004liraglutide other dosesplacebo Exploratory -
Feinglos, 2005liraglutide other dosesmetformin Exploratory Negative
NN2211-1571 (Vilsbøll), 2007liraglutide other dosesplacebo Exploratory NegativeNCT00154401
Seino, 2008liraglutide other dosesplacebo Exploratory NegativeNCT00154414
LEAD-6, 2009liraglutide 1.8mgexenatide on top MET/SU/MET+SU Risk of bias Suggesting NCT00518882
LEAD-3 mono 1.2mg (Garber), 2009liraglutide 1.2mgglimepiride Low risk of bias Negative NCT00294723
LEAD-3 mono 1.8mg (Garber), 2009liraglutide 1.8mgglimepiride Low risk of bias Negative NCT00294723
LEAD-2 (Nauck) (1.2 mg vs glimepiride), 2009liraglutide 1.2mgglimepiride (add on MET) Low risk of bias NegativeNCT00318461
LEAD-2 (Nauck) (1.8 mg vs glimepiride), 2009liraglutide 1.8mgglimepiride (add on MET)NegativeNCT00318461
LEAD-5 (vs Glargine), 2009liraglutide 1.8mginsulin glargine (add on SU+MET) Risk of bias Negative NCT00331851
LEAD-2 (Nauck) (1.8mg vs placebo), 2009liraglutide 1.8mgplacebo (add on MET)SuggestingNCT00318461
LEAD-2 (Nauck) (1.2mg vs placebo), 2009liraglutide 1.2mgplacebo (add on MET)Suggesting NCT00318461
LEAD-1 SU (1.2 mg vs placebo), 2009liraglutide 1.2mgplacebo (add on SU) Low risk of bias Suggesting NCT00318422
LEAD-1 SU (1.8 mg vs placebo), 2009liraglutide 1.8mgplacebo (add on SU)SuggestingNCT00318422
LEAD-5 (vs placebo), 2009liraglutide 1.8mgplacebo (add on SU+MET)Suggesting NCT00331851
LEAD-4 (1.2mg), 2009liraglutide 1.2mgplacebo (add on TZD+MET)SuggestingNCT00333151
LEAD-4 (1.8mg), 2009liraglutide 1.8mgplacebo (add on TZD+MET)SuggestingNCT00333151
LEAD-1 SU (1.8 vs rosiglitazone), 2009liraglutide other dosesrosiglitazone (add on SU) Low risk of bias SuggestingNCT00318422
Seino, 2010liraglutide other dosesglibenclamide Low risk of bias NegativeNCT00393718
Pratley 1.2mg, 2010liraglutide 1.2mgsitagliptin Risk of bias Suggesting NCT00700817
Pratley 1.8mg, 2010liraglutide 1.8mgsitagliptin Low risk of bias Suggesting NCT00700817
LEADER, 2016liraglutideplacebo Exploratory ConclusiveNCT01179048
EAGLE ongoing liraglutide other dosesinsulin glargine - NCT01117350
NN8022-1922 ongoing liraglutide other dosesplacebo - NCT01272232
NCT00978393 ongoing liraglutide other dosesplacebo - NCT00978393
NN2211-1800 ongoing liraglutide other dosesplacebo - NCT00943501
NN2211-1799 ongoing liraglutide other dosesplacebo - NCT00620282
LIBRA ongoing liraglutide other dosesplacebo - NCT01270789
NN2211-3619 ongoing liraglutide other dosesplacebo - NCT01206101
NN8022-1923 ongoing liraglutide other dosesplacebo - NCT00781937
NCT01234649 ongoing liraglutide other dosesplacebo (add on MET) - NCT01234649
NN2211-1701 ongoing liraglutide other dosesplacebo (add on SU) - NCT00395746
MK-0431-403 ongoing liraglutide other dosessitagliptin (add on MET) - NCT01296412

obesity and overweight

Astrup (NN8022-1807 ), 2009liraglutideplacebo - NCT00422058



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons